Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Bilateral generalized polymicrogyria is a rare neurological disorder that affects the cerebral cortex (the outer surface of the brain). This is the most widespread form of polymicrogyria and typically affects the entire surface of the brain. Signs and symptoms include severe intellectual disability, problems with movement, and seizures that are difficult or impossible to treat. While the exact cause of bilateral generalized polymicrogyria is not fully understood, it is thought to be due to improper brain development during embryonic growth. Most cases appear to follow an autosomal recessive pattern of inheritance. Treatment is based on the signs and symptoms present in each person.
Biomarker and diagnostic research for bilateral generalized polymicrogyria has been reported in the published literature.
No clinical trials have been registered for bilateral generalized polymicrogyria.
140 publications have been identified in PubMed for bilateral generalized polymicrogyria. Kisho has analyzed 77 by research type. Research spans Review / Meta-Analysis (38%), Epidemiology / Natural History (19%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 29 | 38% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 11:54 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Disease patterns and progression |
15 |
19% |
Laboratory research | 14 | 18% |
Other research | 8 | 10% |
Testing and diagnosis research | 3 | 4% |
Patient case studies | 3 | 4% |
New treatment approaches | 3 | 4% |
Clinical study results | 2 | 3% |
Hackett AN (2026). [PMID: 41166783](https://pubmed.ncbi.nlm.nih.gov/41166783/). *Pediatr Neurol*. [Gene Therapy / Novel Therapeutics]
Shao Y (2026). [PMID: 41262005](https://pubmed.ncbi.nlm.nih.gov/41262005/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Vossler DG (2026). [PMID: 42066484](https://pubmed.ncbi.nlm.nih.gov/42066484/). *Seizure*. [Review / Meta-Analysis]
John S (2026). [PMID: 41502106](https://pubmed.ncbi.nlm.nih.gov/41502106/). *Epileptic Disord*. [Diagnostic / Biomarker]
Hirsch LJ (2026). [PMID: 41297117](https://pubmed.ncbi.nlm.nih.gov/41297117/). *Clin Neurophysiol*. [Review / Meta-Analysis]
Fathimath M (2026). [PMID: 41617510](https://pubmed.ncbi.nlm.nih.gov/41617510/). *Med J Malaysia*. [Epidemiology / Natural History]
Loushy I (2025). [PMID: 39932255](https://pubmed.ncbi.nlm.nih.gov/39932255/). *Epilepsia*. [Epidemiology / Natural History]
Gould L (2025). [PMID: 40602049](https://pubmed.ncbi.nlm.nih.gov/40602049/). *Pediatr Neurol*. [Epidemiology / Natural History]
Russ JB (2025). [PMID: 40048696](https://pubmed.ncbi.nlm.nih.gov/40048696/). *Brain*. [Review / Meta-Analysis]
Wood C (2025). [PMID: 40329813](https://pubmed.ncbi.nlm.nih.gov/40329813/). *Brain Behav*. [Diagnostic / Biomarker]